Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from technology validation to commercial execution. The 1Q27 results, released in August 2026, demonstrate accelerating momentum, with revenue increasing 54% quarter-over-quarter and 273% year-over-year to $1.28 million. Active buying customers have grown to 40 from 30+, and repeat purchasing is building, providing improved visibility into recurring demand.
Despite the positive revenue trajectory, the company recorded a $1.76 million inventory write-down, which masked a narrower underlying gross loss. According to Stonegate, the focus now shifts to whether the improving customer traction can support the substantial second-half revenue ramp required to achieve the prior CY26 sales objective. The company is also expanding its Galesburg capacity and moving toward positive cash flow, which are critical milestones for investors.
Key takeaways from the update include: Commercialization is gaining traction with revenue up 54% q/q and 273% y/y to $1.28M, active buyers reaching 40, and repeat orders improving recurring-demand visibility. Capacity and funding are now the key execution levers as the planned up-to-$8.1M financing, bridge liquidity, and Galesburg expansion support the production ramp. The second-half ramp remains substantial, with the prior $10M CY26 sales target requiring roughly $7.9M of 2H sales, while positive cash flow remains an important milestone.
Stonegate Capital Partners, a leading capital markets advisory firm, provides investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), offers a full spectrum of investment banking services for public and private companies.
